We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Kenta Biotech Includes First Patient in its First-in-Human Trial of Promising Monoclonal Antibody KBSA301

News   Jun 18, 2012

 
Kenta Biotech Includes First Patient in its First-in-Human Trial of Promising Monoclonal Antibody KBSA301
 
 
 

RELATED ARTICLES

Multi-organ "Human-on-a-Chip" Enables Long-term Toxicology Testing

News

The microfluidic device with interlinking modules containing human-derived heart, liver, skeletal muscle and nervous system cells was able to maintain cellular viability and record cellular function in real-time for 28 days.

READ MORE

Antibody Therapy That Trains Phagocytes to Destroy Tumors Is Tested in Patients

News

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.

READ MORE

Revealing the Critical Role of Heart-derived Macrophages

News

Researchers have identified for the first time the origin of an immune cell that plays a critical role in the formation of healthy heart valves.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE